Intercept Pharmaceuticals Inc (NASDAQ:ICPT) insider David Shapiro sold 2,000 shares of the stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $95.00, for a total transaction of $190,000.00. Following the completion of the transaction, the insider now owns 41,499 shares of the company’s stock, valued at $3,942,405. The sale was disclosed in a document filed with the SEC, which is available through this link.

David Shapiro also recently made the following trade(s):

  • On Wednesday, April 3rd, David Shapiro sold 562 shares of Intercept Pharmaceuticals stock. The stock was sold at an average price of $115.01, for a total transaction of $64,635.62.
  • On Friday, March 1st, David Shapiro sold 2,000 shares of Intercept Pharmaceuticals stock. The stock was sold at an average price of $103.16, for a total transaction of $206,320.00.
  • On Friday, February 15th, David Shapiro sold 2,000 shares of Intercept Pharmaceuticals stock. The stock was sold at an average price of $111.51, for a total transaction of $223,020.00.

Shares of ICPT stock opened at $91.70 on Wednesday. Intercept Pharmaceuticals Inc has a 52 week low of $64.50 and a 52 week high of $133.74. The company has a market capitalization of $2.74 billion, a PE ratio of -8.44 and a beta of 1.63. The company has a debt-to-equity ratio of 19.41, a current ratio of 4.22 and a quick ratio of 4.22.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings results on Thursday, February 28th. The biopharmaceutical company reported ($2.97) EPS for the quarter, missing analysts’ consensus estimates of ($2.42) by ($0.55). Intercept Pharmaceuticals had a negative return on equity of 592.58% and a negative net margin of 172.39%. The company had revenue of $53.30 million during the quarter, compared to the consensus estimate of $52.53 million. During the same quarter in the prior year, the firm earned ($4.43) earnings per share. The business’s revenue was up 41.4% compared to the same quarter last year. Equities research analysts anticipate that Intercept Pharmaceuticals Inc will post -9.13 EPS for the current fiscal year.

Several hedge funds have recently made changes to their positions in ICPT. Prudential Financial Inc. bought a new stake in shares of Intercept Pharmaceuticals in the third quarter worth approximately $293,000. Bank of New York Mellon Corp grew its stake in shares of Intercept Pharmaceuticals by 3.7% in the third quarter. Bank of New York Mellon Corp now owns 93,227 shares of the biopharmaceutical company’s stock worth $11,780,000 after acquiring an additional 3,342 shares during the period. Hsbc Holdings PLC bought a new stake in shares of Intercept Pharmaceuticals in the third quarter worth approximately $748,000. Pacer Advisors Inc. bought a new stake in shares of Intercept Pharmaceuticals in the third quarter worth approximately $417,000. Finally, MetLife Investment Advisors LLC grew its stake in shares of Intercept Pharmaceuticals by 46.0% in the third quarter. MetLife Investment Advisors LLC now owns 14,825 shares of the biopharmaceutical company’s stock worth $1,873,000 after acquiring an additional 4,672 shares during the period. Hedge funds and other institutional investors own 70.24% of the company’s stock.

Several research analysts recently issued reports on the stock. BidaskClub lowered shares of Intercept Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday. B. Riley set a $169.00 price objective on shares of Intercept Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, April 12th. Wedbush set a $251.00 price objective on shares of Intercept Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, April 12th. Wells Fargo & Co raised their price objective on shares of Intercept Pharmaceuticals from $99.00 to $104.00 and gave the company a “market perform” rating in a research note on Friday, April 12th. Finally, UBS Group raised their price objective on shares of Intercept Pharmaceuticals to $139.00 and gave the company a “buy” rating in a research note on Thursday, March 28th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and sixteen have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $144.05.

TRADEMARK VIOLATION NOTICE: This piece of content was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://theolympiareport.com/2019/04/17/intercept-pharmaceuticals-inc-icpt-insider-david-shapiro-sells-2000-shares.html.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.

Featured Article: What are Bollinger Bands?

Insider Buying and Selling by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.